Document is current
Any future updates will be listed below
-
Authors
Charap, Andrew J
Enokida, Tomohiro
Brody, Rachel
Sfakianos, John
Miles, Brett
Bhardwaj, Nina
Horowitz, Amir
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01935921 at ClinicalTrials.govnct02671435 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
nct02643550 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
https://doi.org/10.1136/jitc-2022-004569
518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
https://doi.org/10.1136/ijgc-2020-esgo.147
nct01714739 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2023-007340
nct03341936 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives
https://doi.org/10.1136/jim-2018-000743
nct04294810 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
nct04256421 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies
https://doi.org/10.1136/jitc-2025-014098
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
https://doi.org/10.1136/jitc-2024-008876
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
https://doi.org/10.1136/jitc-2021-003134
nct02608268 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
https://doi.org/10.1200/jco.23.01363
nct03744468 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study (Results)
https://doi.org/10.1136/bmjopen-2023-079132
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
https://doi.org/10.1016/j.ejca.2016.02.020
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
nct01968109 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
nct03311412 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
https://doi.org/10.1136/jitc-2024-009773
Update on the Biology and Management of Renal Cell Carcinoma
https://doi.org/10.1136/jim-2018-000918
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
https://doi.org/10.1200/jco.22.02072
Gene of the month: lymphocyte-activation gene 3 (LAG-3)
https://doi.org/10.1136/jclinpath-2021-207517
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2021-003082
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
https://doi.org/10.1016/j.ejca.2016.02.020
<i>LAG3</i> (<i>LAG-3</i>, <i>CD223</i>) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2020-000552
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
nct02037230 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
nct03319459 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress
https://doi.org/10.1016/j.ijrobp.2016.01.028
nct04290546 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
nct03415100 at ClinicalTrials.govDocuments that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Documents that mention this clinical trial
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
https://doi.org/10.1136/jitc-2020-001523
Chimeric non-antigen receptors in T cell-based cancer therapy
https://doi.org/10.1136/jitc-2021-002628
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R21AI1307601-01)
- License Information
